NYSE - Delayed Quote USD

Ginkgo Bioworks Holdings, Inc. (DNA)

0.9246 +0.0530 (+6.08%)
At close: April 18 at 4:00 PM EDT
0.9100 -0.01 (-1.58%)
After hours: April 18 at 7:54 PM EDT
Loading Chart for DNA
DELL
  • Previous Close 0.8716
  • Open 0.8660
  • Bid --
  • Ask --
  • Day's Range 0.8520 - 0.9541
  • 52 Week Range 0.8500 - 2.5450
  • Volume 39,223,533
  • Avg. Volume 23,088,301
  • Market Cap (intraday) 1.99B
  • Beta (5Y Monthly) 1.36
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4600
  • Earnings Date Mar 1, 2024 - Mar 5, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 1.92

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

www.ginkgobioworks.com

1,218

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DNA

Performance Overview: DNA

Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DNA
45.29%
S&P 500
5.06%

1-Year Return

DNA
24.21%
S&P 500
20.71%

3-Year Return

DNA
--
S&P 500
20.37%

5-Year Return

DNA
--
S&P 500
20.37%

Compare To: DNA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DNA

Valuation Measures

As of 4/19/2024
  • Market Cap

    1.99B

  • Enterprise Value

    1.29B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.15

  • Price/Book (mrq)

    1.81

  • Enterprise Value/Revenue

    5.12

  • Enterprise Value/EBITDA

    -1.57

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -21.82%

  • Return on Equity (ttm)

    -63.02%

  • Revenue (ttm)

    251.46M

  • Net Income Avi to Common (ttm)

    -892.87M

  • Diluted EPS (ttm)

    -0.4600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    944.07M

  • Total Debt/Equity (mrq)

    22.04%

  • Levered Free Cash Flow (ttm)

    -116.14M

Research Analysis: DNA

Analyst Price Targets

1.00
1.92 Average
0.9246 Current
3.00 High
 

Fair Value

Overvalued
% Return
0.9246 Current
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Research Reports: DNA

  • Daily – Vickers Top Buyers & Sellers for 05/23/2023

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Daily – Vickers Top Buyers & Sellers for 10/21/2022

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Daily – Vickers Top Buyers & Sellers for 10/10/2022

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     

People Also Watch